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Fetal Chlorpyrifos Exposure: Adverse Effects on Brain Cell Development 
and Cholinergic Biomarkers Emerge Postnatally and Continue into
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Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, North Carolina, USA
Although some uses of the organophosphate
insecticide chlorpyrifos (CPF)’s were recently
curtailed in the United States (U.S. EPA
2000), CPF and other organophosphates con-
tinue to be applied worldwide on a major
scale. Studies with animal and cell culture
models of CPF exposure indicate that CPF is
especially damaging to the developing brain,
targeting diverse events in neural development,
including cell proliferation and differentiation,
axonogenesis and synaptogenesis, and synaptic
function (see reviews in Barone et al. 2000;
Pope 1999; Rice and Barone 2000; Slotkin
1999); although some developmental toxicant
effects may be unique to CPF, major features
of its actions are shared by related organophos-
phates as well as carbamates (Mileson et al.
1998; Pope 1999; Qiao et al. 2001). The mix-
ture of mechanisms underlying CPF’s actions
renders the developing brain vulnerable to
adverse effects over a broad period, spanning
prenatal and postnatal stages (Barone et al.
2000; Lassiter et al. 1998, 2002; Moser and
Padilla 1998; Pope 1999; Qiao et al. 2002;
Rice and Barone 2000; Slotkin 1999). Indeed,
interference with cell proliferation and differ-
entiation extends to glia, which continue to
proliferate into adolescence (Barone et al.
2000; Garcia et al. 2001, 2002; Monnet-
Tschudi et al. 2000; Qiao et al. 2001).
We recently compared biochemical indices
of brain cell damage in developing rats exposed
to CPF prenatally or postnatally (Garcia et al.
2002; Qiao et al. 2002; Slotkin 1999) and
found that postnatal exposure had a greater,
immediate effect on the number of brain cells
and on indices of synaptic development. On
the surface, this seemed somewhat surprising,
given that CPF readily crosses the placenta to
enter the fetal brain and actually achieves
higher concentrations than in the maternal
brain (Hunter et al. 1999; Lassiter et al. 1998).
Indeed, when we examined more selective
indices of neuronal development, there was
some evidence for speciﬁc disruption of acetyl-
choline systems after prenatal exposure, even at
CPF doses below the threshold for fetal growth
impairment or for inhibition of fetal brain
cholinesterase (Qiao et al. 2002). Preliminary
morphologic studies indicate that prenatal
CPF does affect brain cell development but
with a more focal pattern than is likely to be
the case for postnatal CPF (Lassiter et al. 2002;
White et al. 2002). Indeed, when animals
given prenatal CPF were evaluated for behav-
ioral performance in adolescence and adult-
hood, they displayed deficits in cognitive
behaviors that depend speciﬁcally upon septo-
hippocampal cholinergic function, and showed
selective loss of the cholinergic components of
working and reference memory (Levin et al.
2002). We previously identiﬁed similar, late-
arising behavioral deﬁcits in animals exposed
to CPF postnatally (Levin et al. 2001), effects
that were accompanied by delayed neurotoxic
changes in neurochemical indices of choliner-
gic synaptic activity (Slotkin et al. 2001) and
in other neurotransmitter systems regulated
by cholinergic input (Slotkin et al. 2002).
The neurochemical changes were most
notable for regions of the forebrain (cerebral
cortex, hippocampus, striatum) involved in
learning and memory.
The present study takes a similar approach
to the mechanisms underlying the neurobe-
havioral anomalies associated with prenatal
CPF exposure, addressing two specific ques-
tions: First, are there immediate or delayed
deﬁcits in cholinergic innervation or choliner-
gic synaptic function in the same forebrain
areas that are compromised by postnatal CPF
administration? Second, are these effects sepa-
rable from general cellular abnormalities, such
as alterations in the number of cells or in the
cell protein complement? For cholinergic
synaptic development, we assessed choline
acetyltransferase (ChAT) activity and the bind-
ing of [3H]hemicholinium-3 (HC-3) to the
high-afﬁnity presynaptic choline transporter.
ChAT, the enzyme responsible for acetyl-
choline biosynthesis, is a constitutive marker
for cholinergic nerve terminals and serves as an
archetypal measure of cholinergic innervation,
but its activity does not respond to changes in
impulse flow. Accordingly, ChAT increases
during cholinergic synaptogenesis but does not
change in response to stimuli that alter cholin-
ergic neuronal activity (Aubert et al. 1996;
Happe and Murrin 1992; Navarro et al. 1989;
Slotkin et al. 1990; Zahalka et al. 1992,
1993a). In contrast, high-affinity choline
uptake, as assessed with the binding of HC-3
to the presynaptic high-afﬁnity choline trans-
porter, is responsive to neuronal activity
(Klemm and Kuhar 1979; Simon et al.
1976), and the comparative changes in ChAT
and HC-3 binding or transporter function
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Fetal and childhood exposures to widely used organophosphate pesticides, especially chlorpyrifos
(CPF), have raised concerns about developmental neurotoxicity. Previously, biomarkers for brain
cell number, cell packing density, and cell size indicated that neonatal rats were more sensitive to
CPF than were fetal rats, yet animals exposed prenatally still developed behavioral deﬁcits in ado-
lescence and adulthood. In the present study, we administered CPF to pregnant rats on gestational
days 17–20, using regimens devoid of overt fetal toxicity. We then examined subsequent develop-
ment of acetylcholine systems in forebrain regions involved in cognitive function and compared
the effects with those on general biomarkers of cell development. Choline acetyltransferase, a con-
stitutive marker for cholinergic nerve terminals, showed only minor CPF-induced changes during
the period of rapid synaptogenesis. In contrast, hemicholinium-3 binding to the presynaptic
choline transporter, which is responsive to nerve impulse activity, displayed marked suppression in
the animals exposed to CPF; despite a return to nearly normal values by weaning, deficits were
again apparent in adolescence and adulthood. There was no compensatory up-regulation of
cholinergic receptors, as m2-muscarinic cholinergic receptor binding was unchanged. CPF also
elicited delayed-onset alterations in biomarkers for general aspects of cell integrity, with reduc-
tions in cell packing density, increases in relative cell size, and contraction of neuritic extensions;
however, neither the magnitude nor timing of these changes was predictive of the cholinergic
defects. The present findings indicate a wide window of vulnerability of cholinergic systems to
CPF, extending from prenatal through postnatal periods, occurring independently of adverse
effects on general cellular neurotoxicity. Key words: brain development, chlorpyrifos, choline
acetyltransferase, cholinesterase, development, DNA, hemicholinium-3 binding, muscarinic m2-
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outgrowth as distinct from synaptic activity
(Aubert et al. 1996; Happe and Murrin
1992; Navarro et al. 1989; Slotkin et al.
1990; Zahalka et al. 1992, 1993a). These
markers have been used previously to charac-
terize effects of CPF on cholinergic systems in
adult rats (Liu and Pope 1996, 1998) and to
evaluate the immediate and delayed effects of
postnatal CPF exposure (Dam et al. 1999;
Slotkin et al. 2001). We also measured radi-
oligand binding to the m2-muscarinic acetyl-
choline receptor (m2AChR), a mediator of
cholinergic signaling that typically undergoes
down-regulation in the presence of choliner-
gic hyperstimulation (Bushnell et al. 1993;
Chakraborti et al. 1993; Ward and Mundy
1996) and that may also be a direct target for
CPF actions (Bomser and Casida 2001; Huff
et al. 1994).
Measurements of DNA and cell protein
fractions were used to evaluate CPF’s general
effects on cell development. Because each
neural cell contains only a single nucleus
(Winick and Noble 1965), the DNA content
(amount of DNA in each brain region)
reflects the total number of cells, and the
DNA concentration (DNA per unit tissue
weight) reﬂects the cell packing density (Bell
et al. 1987; Slotkin et al. 1984; Winick and
Noble 1965); these indices are affected by
postnatal CPF exposure (Campbell et al.
1997; Dam et al. 1998; Song et al. 1998;
Whitney et al. 1995). We also assessed the
complement of cell proteins related to differ-
entiation as opposed to cell numbers. As neu-
rons specialize, they enlarge and develop
axonal and dendritic projections. The ratio of
total protein/DNA thus rises with the expan-
sion of the cell (Bell et al. 1987; Slotkin et al.
1984). In cells that do not develop projec-
tions, the membrane surface-to-volume ratio
falls as the cell enlarges, such that the mem-
brane protein concentration falls with hyper-
trophy (Thai et al. 1996); however, for neural
cells, the development of neuritic projections
necessitates a rise in the contribution of
membrane proteins relative to other cell pro-
teins. Accordingly, we also assessed the mem-
brane protein concentration and the ratio of
membrane proteins to total cell proteins.
Methods
Animal treatments. Studies were carried out
with the approval of the Duke University
Institutional Animal Care and Use Committee,
in accordance with the declaration of
Helsinki and with the Guide for the Care and
Use of Laboratory Animals as adopted and
promulgated by the National Institutes of
Health. Timed-pregnant Sprague-Dawley
rats were housed in breeding cages with a 12-
hr light/dark cycle and with free access to
food and water. CPF was dissolved in
dimethyl sulfoxide to provide rapid and
complete absorption (Whitney et al. 1995)
and was injected subcutaneously in a volume
of 1 mL/kg body weight; control animals
received vehicle injections on the same
schedule. Animals received 0, 1, or 5 mg/kg
daily on gestational days 17–20 (GD17–20);
these doses span the threshold for inhibition
of fetal brain cholinesterase activity (Qiao et
al. 2002) but lie below the threshold for fetal
growth impairment or effects on fetal viabil-
ity (Garcia et al. 2002; Qiao et al. 2002). On
the day after birth, pups were randomized
within treatment groups and redistributed to
the nursing dams with a litter size of 10, so
as to maintain standardized nutrition.
Randomization was repeated at intervals of
several days, and in addition, dams were
rotated among litters to distribute any mater-
nal caretaking differences randomly across
litters and treatment groups. Animals were
weaned on postnatal day 21 (PN21).
Animals were decapitated and brain
regions were dissected using the natural land-
marks of the neonatal rat brain: blunt cuts
were made through the cerebellar peduncles,
whereupon the cerebellum (including floc-
culi) was lifted from the underlying tissue. A
cut was then made rostral to the thalamus to
isolate the forebrain, thus including the cor-
pus striatum, hippocampal formation, and
neocortex within the area designated “fore-
brain.” For studies on PN30 and PN60, the
forebrain was divided into the cerebral cortex,
hippocampus, and striatum. Tissues were
frozen with liquid nitrogen and maintained at
–45°C. At each age, each treatment group
included 8–16 animals, evenly divided
between males and females; the number of
animals in each of the CPF groups was always
matched to an equal number of controls, and
determinations used no more than one male
and one female from each litter. All assays
were run such that all the animals for the
control and both CPF groups were evaluated
simultaneously to ensure that day-to-day vari-
ations in assays did not generate spurious
treatment effects. Each assay included stan-
dards that were run with each batch to ensure
day-to-day replication of values.
Cholinergic biomarkers. Tissues were
thawed in 79 volumes of ice-cold 10 mM
sodium-potassium phosphate buffer (pH 7.4)
and homogenized with a Polytron (Brinkmann
Instruments, Westbury, NY). For ChAT activ-
ity, assays (Lau et al. 1988) contained 30 µL of
diluted homogenate in a total volume of 60 µL
with final concentrations of 60 mM sodium
phosphate (pH 7.9), 200 mM NaCl, 20 mM
choline chloride, 17 mM MgCl2, 1 mM
EDTA, 0.2% Triton X-100, 0.12 mM
physostigmine, 0.6 mg/mL bovine serum albu-
min, and 50 µM [14C]acetyl-coenzyme A.
Blanks contained homogenization buffer
instead of the tissue homogenate. Samples
were preincubated for 15 min on ice and
transferred to a 37°C water bath for 30 min,
and the reaction was terminated by placing
the samples on ice. Labeled acetylcholine was
then extracted and counted and the activity
determined relative to tissue protein (Smith
et al. 1985). Preliminary determinations
established that enzyme activity was linear
with time and tissue concentration under
these conditions.
For measurements of [3H]HC-3 binding,
an aliquot of the same tissue homogenate was
sedimented at 40,000 × g for 15 min and the
supernatant solution was discarded. The
membrane pellet was resuspended (Polytron)
in the original volume of buffer and resedi-
mented, and the resultant pellet was resus-
pended using a smooth glass homogenizer
ﬁtted with a Teﬂon pestle, in 10 mM sodium-
potassium phosphate buffer (pH 7.4) and 150
mM NaCl. Radioligand binding was evalu-
ated with 2 nM [3H]HC-3 (Vickroy et al.
1984), with incubation for 20 min at room
temperature, followed by rapid vacuum ﬁltra-
tion onto Whatman GF/C ﬁlters (presoaked
for 30 min with 0.1% polyethyleneimine in
buffer). The nonspecific component was
deﬁned as radioligand binding in the presence
of an excess concentration of unlabeled HC-3
(10 µM). Binding values were expressed rela-
tive to membrane protein. The selection of a
single, subsaturating concentration of radioli-
gand for the binding analysis enables the
detection of changes in either Kd or Bmax but
does not permit distinction between effects on
the two parameters. This strategy was necessi-
tated by two factors. First, the amount of tis-
sue in each neonatal brain region was
insufficient for the multiple determinations
required for Scatchard analysis. Second, we
needed to measure binding in hundreds of
membrane preparations, involving three treat-
ment groups and four tissues at multiple ages,
each involving as many as 16 individual ani-
mals in each group at each age point, while
making sure to evaluate age-matched control
and treated groups simultaneously. Previous
work has shown that developmental changes
in HC-3 binding reﬂect almost exclusively a
change in Bmax (Zahalka et al. 1993a); how-
ever, the interpretation of results of the pre-
sent study, which relate to HC-3 binding as
an index of neural activity (Cheney et al.
1989; Jope 1979; Murrin 1980; Navarro et al.
1989; Shelton et al. 1979; Simon et al. 1976;
Zahalka et al. 1992, 1993a), does not depend
on a change in a speciﬁed parameter.
For m2AChR binding, membranes from
the same tissue homogenate were prepared
by a slightly different protocol from that
used for HC-3 binding (Zahalka et al.
1993b). The original tissue homogenate was
diluted with an equal volume of 10 mM
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sodium-potassium phosphate buffer (pH 7.4)
and sedimented at 40,000×g for 10 min. The
resultant pellet was resuspended in phosphate
buffer, and the membranes were incubated
for 60 min at room temperature, using 1 nM
[3H]AFDX384 with or without 1 µM
atropine to displace speciﬁc binding.
Macromolecules. DNA was determined in
aliquots of the same tissue homogenates used
for cholinergic biomarkers, using a modiﬁed
(Trauth et al. 2000) ﬂuorescent dye–binding
method (Labarca and Piagen 1980). Aliquots
were homogenized in 50 mM sodium phos-
phate, 2 M NaCl, 2 mM EDTA (pH 7.4) and
sonicated briefly (Virsonic Cell Disrupter;
Virtis, Gardiner, NY). Hoechst 33258 was
added to a final concentration of 1 µg/mL.
Samples were then read in a spectroﬂuorom-
eter using an excitation wavelength of 356
nm and an emission wavelength of 458 nm,
and were quantitated using standards of
purified DNA. The total concentration of
tissue proteins was assayed from the original
homogenate spectrophotometrically with
bicinchoninic acid (Smith et al. 1985); in
addition, we assessed the concentration of
membrane proteins, averaging the values
obtained for the two membrane preparations
used for HC-3 and m2AChR radioligand
binding.
Data analysis. To avoid type I statistical
errors in subdividing the data into the differ-
ent measures, brain regions, ages, and sexes,
we ﬁrst performed global analyses of variance
(ANOVAs) on data groupings corresponding
to the four classes of measurements: weights,
cholinergic biomarkers (ChAT, HC-3 bind-
ing, m2AChR binding), indices dependent on
the number of cells (DNA content and con-
centration), and indices related to cell proteins
(total protein/DNA, membrane protein con-
centration, membrane protein/total protein).
Because each tissue homogenate contributed
multiple assessments in each category, the var-
ious determinations were treated as repeated
Table 1. Development of biomarkers in control brain regions (males and females combined).
Cholinergic biomarkers DNA biomarkers Cell protein biomarkers
ChAT HC-3 m2AChR DNA DNA Membrane
(pmol/mg (fmol/mg (fmol/mg concentration content Total protein Membrane/
Control brain regions protein/min) protein) protein) (mg/g tissue) (µg/region) Protein/DNA (mg/g tissue) total protein
Forebrain
PN4 20 ± 1 10.0 ± 0.7 121 ± 6 1.54 ± 0.03 475 ± 13 67 ± 1 19.3 ± 0.4 0.189 ± 0.004
PN10 120 ± 2 10.4 ± 0.6 307 ± 6 1.06 ± 0.01 700 ± 10 68 ± 1 25.3 ± 0.5 0.353 ± 0.007
PN15 287 ± 8 10.8 ± 0.6 439 ± 7 0.99 ± 0.02 821 ± 18 91 ± 2 31.8 ± 0.6 0.357 ± 0.009
PN21 606 ± 5 12.2 ± 0.8 441 ± 5 0.92 ± 0.01 863 ± 15 103 ± 2 37.2 ± 0.7 0.397 ± 0.009
ANOVA age, p < 0.0001 NS age, p < 0.0001 age, p < 0.0001 age, p < 0.0001 age, p < 0.0001 age, p < 0.0001 age, p < 0.0001
sex, 0.02
Repeated measures  age, p < 0.0001; measure, p < 0.0001;  sex, p < 0.04; measure, p < 0.0001; age × measure, age, p < 0.0001; measure, p < 0.0001; 
ANOVA (forebrain) age × measure, p < 0.0001 p < 0.0001; sex × measure, p < 0.02 age × measure, p < 0.0001; sex × measure, p < 0.03
Cerebral cortex
PN30 436 ± 7 17.9 ± 0.6 495 ± 12 0.91 ± 0.01 710 ± 9 108 ± 2 34.9 ± 0.5 0.355 ± 0.006
PN60 405 ± 11 14.0 ± 0.5 377 ± 6 0.68 ± 0.02 615 ± 19 152 ± 4 42.3 ± 0.9 0.413 ± 0.009
ANOVA age, p < 0.02;  age, p < 0.0005 age, p < 0.0001 age, p < 0.0001; age, p < 0.0001; age, p < 0.0001 age, p < 0.0001 age, p < 0.0001
sex, p < 0.05 sex, p < 0.02 sex, p < 0.05; 
age × sex, p < 0.005
Hippocampus
PN30 418 ± 16 12.3 ± 0.6 392 ± 8 0.75 ± 0.02 79 ± 3 116 ± 4 32.1 ± 0.6 0.368 ± 0.006
PN60 499 ± 12 14.3 ± 1.3 310 ± 4 0.64 ± 0.01 76 ± 3 135 ± 2 38.5 ± 0.5 0.452 ± 0.007
ANOVA age, p < 0.0001; NS age, p < 0.0001 age, p < 0.0001; age × sex, age,  p < 0.0001 age, p < 0.0001 age, p < 0.0001
sex, p < 0.005 age × sex, p < 0.05 p < 0.009
Striatum
PN30 1,088 ± 30 75.3 ± 4.3 538 ± 12 0.87 ± 0.01 91 ± 5 110 ± 2 38.6 ± 0.4 0.408 ± 0.006
PN60 1,229 ± 84 67.3 ± 5.4 427 ± 17 0.57 ± 0.03 73 ± 6 133 ± 13 41.0 ± 2.1 0.570 ± 0.042
ANOVA NS age × sex, age,  p < 0.0001;  age, p < 0.0001 age, p < 0.05 NS sex, p < 0.04; age, p < 0.003
p < 0.003 age × sex, age  × sex,
p < 0.04 p < 0.02
ANOVA (3 regions) age,  region,  age,  age, age, age,  age,  age,
p < 0.009;  p < 0.0001; p < 0.0001; p < 0.0001; p < 0.0001;  p < 0.0001;  p < 0.0001;  p < 0.0001;
region, age × region, region, region, region,  age  × region, region, region,
p < 0.0001; p < 0.004;  p < 0.0001; p < 0.0001;  p < 0.0001;  p < 0.007 p < 0.0001; p < 0.0001;
sex, age  × sex, age × sex, age × region, age  × region, age  × region, age × region,
p < 0.003; p < 0.03;  p < 0.04;  p < 0.0001; p < 0.06;  p < 0.002;  p < 0.04; 
age × region, age × region age × region sex  × region, age  × region age  × sex, age  × sex,
p < 0.0004 × sex,  × sex, p < 0.02; × sex, p < 0.03; p < 0.06
p < 0.02 p < 0.1 age × region  p < 0.04 sex × region,
× sex, p < 0.02; 
p < 0.007 age × region × sex, 
p < 0.02
Repeated measures
ANOVA (three regions) age, p < 0.0001; region, p < 0.0001;  age, p < 0.0001; region, p < 0.0001;  age, p < 0.0001; region, p < 0.0001;
age × region, p < 0.0001;  age × region, p < 0.0009;  age × region, p < 0.06;
age × sex, p < 0.02;  age × region × sex, p < 0.02;  age × sex, p < 0.03;
age × region × sex, p < 0.0006; measure, p < 0.0001;  measure, p < 0.0001;
measure, p < 0.0001;  age × measure, p < 0.0001; age × measure, p < 0.05;
age × measure, p < 0.0001;  region × measure, p < 0.0001;  region × measure, p < 0.0001; 
region × measure, p < 0.0001;  sex × measure, p < 0.01, age × region × measure, p < 0.0005; 
sex × measure, p < 0.09; age × sex × measure, p < 0.04 region × sex × measure, p < 0.05, 
age × region × measure, p < 0.1 age × region × sex × measure, p < 0.04
NS, not signiﬁcant. 
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tial test indicated treatment effects that dif-
fered among the different measures, so data
were then examined separately for each mea-
sure, again using a multivariate ANOVA
(treatment, region, age, sex). Where appro-
priate, this was followed by post hoc evalua-
tions of each treatment group compared with
the controls, with Fisher’s protected least sig-
niﬁcant difference; however, where treatment
effects did not interact with other variables,
only the main effect was recorded without
testing of individual differences. Signiﬁcance
was assumed at the level of p < 0.05 for main
effects; however, for interactions at p < 0.1,
we also examined whether lower-order main
effects were detectable after subdivision of
the interactive variables (Snedecor and
Cochran 1967).
Values from birth to PN21 were deter-
mined in the forebrain, whereas in older ani-
mals the forebrain was subdivided into its
constituent subregions. Accordingly, the
global tests incorporated two data groupings
corresponding to these separable regions and
ages. However, the cerebral cortex consti-
tuted approximately 80% of the forebrain
weight; accordingly, we verified differences
across the two age groupings by performing
ANOVAs incorporating all ages and compar-
ing treatment effects in the forebrain and
cerebral cortex.
Data are presented as means and stan-
dard errors. To facilitate comparisons across
multiple tissues, ages, and variables, the
effects of CPF are given as the percentage
change from the corresponding control
group, but statistical comparisons were made
on the original data.
Materials. Animals were purchased from
Zivic Laboratories (Pittsburgh, PA), and
CPF was obtained from Chem Service Inc.
(West Chester, PA). Dimethyl sulfoxide was
purchased from Mallinckrodt Baker (Paris,
KY). [14C]Acetyl-coenzyme A (speciﬁc activ-
ity, 44 mCi/mmol; diluted with unlabeled
compound to 6.7 mCi/mmol), [3H]HC-3
(specific activity, 161 Ci/mmol), and
[3H]AFDX384 (specific activity, 133
Ci/mmol) were obtained from PerkinElmer
Life Sciences (Boston, MA). Sigma Chemical
Co. (St. Louis, MO) was the source for all
other reagents.
Results
Development of biomarkers in control brain
regions. Variables reﬂecting cholinergic synap-
tic outgrowth showed distinctly different
ontogenetic profiles from those delineating
general cell development. Table 1 shows com-
parisons among the different biomarkers for
control rat brain regions from PN4 through
PN60; statistical evaluations were conducted
first by repeated-measures ANOVA for the
three groupings (cholinergic biomarkers,
DNA biomarkers, cell protein biomarkers)
and then, as justified by the interactions of
development (age) with other variables, by
ANOVA across regions for each separate
marker, and finally by ANOVA for each
region. At each sequential stage, we looked for
sex differences, and where there were none, we
disregarded any sex differences that appeared
in lower-order tests so as to avoid type I statis-
tical errors. Where the sex differences were
maintained, we examined individual values for
which males and females differed. The values
represent males and females combined
because, although sex was signiﬁcant in overall
testing for some variables, there were actually
very few individual differences, and these are
identiﬁed below.
Not surprisingly, body and brain region
weights increased monotonically with devel-
opment (data not shown), with significant
differences between males and females that
showed increasing divergence with age: body
weight, main effect of sex (p < 0.0001), age ×
sex interaction (p < 0.0001); forebrain from
PN4 to PN21, main effect of sex (p < 0.02);
brain regions on PN30 and PN60, main
effect of sex (p < 0.02), age × sex interaction
(p < 0.02). By PN60, males weighed approxi-
mately 400 g, whereas females weighed about
260 g. Brain region weights showed smaller
sex differences, ranging from only a few per-
centage points to 10% lower values in females
by PN60 (data not shown).
ChAT activity showed marked develop-
mental increases in the forebrain over the ﬁrst
3 postnatal weeks, corresponding to the
period of rapid synaptogenesis (Table 1).
Values in the three subregions then stabilized
by PN30, such that only minor changes were
evident thereafter; the striatum showed the
highest ChAT activity. HC-3 binding, which
is responsive to nerve impulse activity,
showed a different pattern, with only a small
increase over the first 3 weeks and larger
increases thereafter. The subregions again
showed marked differences from each other,
with striatal values much higher than those in
the cerebral cortex or hippocampus. m2AChR
binding, like ChAT activity, showed substan-
tial increases in the forebrain between PN4
and PN21; values then declined slightly in all
subregions between PN30 and PN60. There
were signiﬁcant sex differences for two of the
cholinergic biomarkers: females averaged 5%
higher values for ChAT in the cerebral cortex
(main effect of sex), and 13% higher for the
hippocampus (main effect of sex); striatal
HC-3 binding showed overall sex differences
Environmental Health Perspectives • VOLUME 111 | NUMBER 4 | April 2003 539
Articles | Developmental neurotoxicity of chlorpyrifos
Figure 1. Effects of prenatal CPF exposure on postnatal development of cholinergic biomarkers: (A) ChAT activity; (B) HC-3 binding; and (C) m2AChR binding. NS,
not signiﬁcant. Data are presented as percentage change from control values (Table 1), at the postnatal ages (days) indicated on the abscissa. Until weaning,
measurements were made in the whole forebrain; for determinations in adolescence and adulthood, the forebrain was divided into its constituent subregions:
cerebral cortex, hippocampus, striatum. ANOVA results across ages and regions appear at the bottom of A–C. Tests of individual points where the CPF group dif-
fers from the corresponding control were carried out only where the global test indicated an interaction of treatment × age; this occurred only for the forebrain,
which showed a main treatment effect across the ﬁrst three age points in the low-dose group (arrows) and a decrease on PN21 (asterisk). Testing of individual
subregions on PN30 and PN60 was not conducted because of the absence of a treatment × region interaction. Results for males and females were combined
because of the absence of a treatment × sex effect.
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As expected by the transition of neural
cells from mitosis to differentiation, the DNA
concentration in the forebrain was high on
PN4 and fell over the ensuing 3 weeks
(Table 1). Nevertheless, because the regional
weight increased 3-fold over the same period,
the DNA content approximately doubled,
representing the continued acquisition of new
cells through at least PN21. The DNA con-
centration and content in the subregions con-
tinued to decline slightly between PN30 and
PN60. DNA content showed significant sex
differences that reflected the slightly larger
brain region weights in males: males averaged
5% higher values in the forebrain during the
preweaning period, rising to 15% in the cere-
bral cortex and hippocampus by PN60.
In keeping with postnatal growth of
neural cells and the expansion of cell surface
area attending axonogenesis and synaptogene-
sis, all three indices of cell proteins showed
substantial age-related increments (Table 1).
The ratio of total cell proteins to DNA (pro-
tein per cell) nearly doubled between PN4
and PN21 in the forebrain, and the subre-
gions showed further increments between
PN30 and PN60. The membrane protein
concentration, which more closely represents
expansion of the cell surface area, showed
larger proportional increases; this was veriﬁed
by comparison of ratio of membrane protein
to total protein, which showed signiﬁcant aug-
mentation with age in the forebrain and across
the three subregions. Although development
of the cell protein markers showed an overall
sex dependence, none of the values was signiﬁ-
cant when assessed individually for the fore-
brain, and only one difference was noted in
the subregions (higher values for females in
the striatum on PN60).
All the biomarkers chosen to reflect
cholinergic synaptic development and func-
tion, cell numbers, and cell protein comple-
ment showed robust developmental changes
from birth to adulthood. Accordingly, these
indices were evaluated to characterize the
potential for delayed neurotoxicity after pre-
natal CPF exposure.
General effects of CPF. In agreement with
earlier results (Qiao et al. 2002), the two CPF
doses used here straddled the threshold for
impairment of maternal growth but did not
alter litter size, neonatal viability, or the sex
ratio. The weight gain from the start of treat-
ment (GD17) to the last day of treatment
(GD20) was 49 ± 2 g in controls (n = 35) and
46 ± 2 g in the group receiving 1 mg/kg/day
of CPF (n = 35, not significant vs. control)
but only 31 ± 3 g in the 5 mg/kg/day group
(n = 32, p < 0.0001 compared with controls
or the low-dose group). Nevertheless, there
was no reduction in the number of offspring
(12.9 ± 0.3 in controls, 12.7 ± 0.3 in the 1
mg/kg/day group, 12.4 ± 0.3 in the
5 mg/kg/day group, not signiﬁcant), nor were
there any alterations in neonatal viability.
Body weight of the offspring showed no sig-
nificant differences throughout the period
from PN4 to PN60 (data not shown). There
was a statistically signiﬁcant overall difference
in forebrain weights (p < 0.02 for main treat-
ment effect; p < 0.03 for treatment × age),
but after subdivision into the individual ages,
only one age displayed differences: on PN4,
control forebrain weight was 310 ± 4 mg,
compared with 309 ± 4 mg in the group
exposed to the low dose of CPF (not signiﬁ-
cant) and 284 ± 6 mg in the high-dose group
(p < 0.002). All other ages were not signifi-
cant, nor were there any statistically signifi-
cant differences across the three brain regions
for measurements on PN30 and PN60 (data
not shown).
Before evaluating the effects of CPF on
each individual biomarker, global statistical
analyses were conducted across the three
classes of measurements to protect against
type I statistical errors and to validate the sub-
division into separate determinations. For the
cholinergic assessment battery (ChAT, HC-3
binding, m2AChR binding), repeated-mea-
sures ANOVA across all ages in the forebrain
indicated a main treatment effect of CPF (p <
0.05) and interactions of treatment × measure
(p < 0.005) and treatment × age × measure (p
< 0.06). Examination of the three subregions
on PN30 and PN60 showed similar global
effects: main treatment effect (p < 0.007) and
treatment × measure interaction (p < 0.0003).
Because the cerebral cortex represents 80% of
the forebrain tissue mass, we also evaluated
the cholinergic markers across all six age
points for the forebrain and cerebral cortex,
and again obtained the same effects and inter-
actions: main treatment effect (p < 0.0009),
treatment × measure (p < 0.0001), treatment
× age × measure (p < 0.1).
For the grouping of variables related to
the number of cells (DNA concentration,
DNA content), values from PN4 through
PN21 for the forebrain displayed a main
treatment effect (p < 0.03) and interactions of
treatment × measure (p < 0.02) and treatment
× age × measure (p < 0.03). For the sub-
regions on PN30 and PN60, although the
main effect of CPF was at the margin of sig-
niﬁcance (p < 0.06), the interaction of treat-
ment with the other variables was statistically
signiﬁcant (treatment × age × region × meas-
ure, p < 0.05). Combining the measurements
in the forebrain with those in the cerebral
cortex so as to evaluate effects over all six age
points, CPF affected the DNA-related vari-
ables in an interactive manner: treatment ×
age (p < 0.03), treatment × measure (p < 0.1),
treatment × age × measure (p < 0.04), treat-
ment × age × sex × measure (p < 0.03).
The measures of cell proteins (total pro-
tein/DNA, membrane protein concentration,
membrane/total protein) similarly showed
effects at all levels. For the preweaning age
points in the forebrain, there were interac-
tions of treatment × measure (p < 0.004) and
treatment × age × measure (p < 0.07). The
subregions on PN30 and PN60 displayed
interactions of treatment × age (p < 0.1),
treatment × age × sex (p < 0.08), treatment ×
measure (p < 0.002), and treatment × age ×
region × sex × measure (p < 0.02). The full
time course, evaluated across the forebrain
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Figure 2. Effects of prenatal CPF exposure on postnatal development of biomarkers for (A) cell packing
density (DNA concentration = DNA/g tissue) and (B) cell number (DNA content = DNA/region). NS, not sig-
niﬁcant. Data are presented as percentage change from control values (Table 1), at the p/ostnatal ages
(days) indicated on the abscissa. Until weaning, measurements were made in the whole forebrain; for
determinations in adolescence and adulthood, the forebrain was divided into its constituent subregions.
ANOVA results across ages and regions appear at the bottom of A and B. Tests of individual points where
the CPF group differs from the corresponding control were carried out only where the global test indicated
an interaction of treatment × age; this occurred only for the forebrain, which showed an effect in the high-
dose group on PN4 (asterisk). Testing of individual subregions on PN30 and PN60 was not conducted
because of the absence of a treatment × region interaction. Results for males and females were combined
because of the absence of a treatment × sex effect.
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CPF 5 mg/kgand cerebral cortex, exhibited a significant
main CPF effect (p < 0.03), with interactions
of treatment × age × measure (p < 0.0009)
and treatment × sex × measure (p < 0.07).
Based on the interaction terms obtained in
the global statistical tests, we subdivided the
data into the separate measures for each of the
three classes of determinations. Lower-order
tests were then conducted, and except where
noted, these did not show interactions of treat-
ment × sex or treatment × sex × other variables.
Accordingly, data were combined for males and
females for presentation, but the factor of sex
was retained in the statistical design.
Effects on cholinergic biomarkers. During
the rapid forebrain growth spurt, when
ChAT activity was increasingly dramatic
(Table 1), animals exposed prenatally to CPF
showed small but statistically significant
changes (Figure 1A). Animals receiving the
low-dose regimen displayed initial enhance-
ment of ChAT, followed by deficits on
PN21. Examining the subregions on PN30
and PN60 revealed no significant difference
across the cerebral cortex, hippocampus, or
striatum. However, regarding the cerebrocor-
tical values as a continuation of those in the
forebrain indicated that the delayed deficits
persisted through PN30: ANOVA across all
ages for the forebrain and cerebral cortex
indicated a treatment × age interaction (p <
0.01), with signiﬁcant deﬁcits for PN21 and
PN30 (p < 0.007). By PN60, ChAT activities
were not distinguishable from control values.
In contrast to the small changes in ChAT,
prenatal CPF exposure had marked effects on
HC-3 binding (Figure 1B). During the
preweaning phase, there were initial deficits
of 20–30%, and although values tended to
resolve to normal limits by weaning, binding
was again subnormal in adolescence and
adulthood. Again, comparing across all six
age points by incorporating the forebrain in
the preweaning period with the cerebral cor-
tex for PN30 and PN60 gave the same result:
a significant main treatment effect of CPF
(p < 0.0001). The magnitude of the effect of
CPF on HC-3 binding was statistically distin-
guishable from that on ChAT (p < 0.02 for
treatment × measure in the forebrain or in
the three subregions).
Because HC-3 binding is responsive to
cholinergic nerve impulse activity, whereas
ChAT is a static marker for nerve terminals,
the ratio of HC-3 binding to ChAT activity
represents an index of activity per nerve termi-
nal (Aubert et al. 1996; Happe and Murrin
1992; Navarro et al. 1989; Slotkin et al. 1990;
Zahalka et al. 1992, 1993a). Accordingly, we
also evaluated the effects of CPF on this ratio,
using the primary data from Figure 1. For the
forebrain values in preweaning animals, CPF
elicited significant reductions in the HC-
3:ChAT ratio (p < 0.02 overall; p < 0.008 for
control vs. CPF 1 mg/kg/day; p < 0.02 for
control vs. CPF 5 mg/kg/day). Similarly, the
subregional determinations on PN30 and
PN60 indicated a reduction in the activity
ratio (p < 0.02 overall; p < 0.04 for control vs.
CPF 1 mg/kg/day; p < 0.004 for control vs.
CPF 5 mg/kg/day).
The changes in ChAT activity and HC-3
binding were selective in that they were not
shared by a different cholinergic marker,
m2AChR binding (Figure 1C). The lack of
significant differences was apparent during
both the phase of rapid receptor acquisition
(PN4–21) and subsequent postweaning
decline (PN30–60). The same result was
obtained when values for the forebrain and
cerebral cortex were evaluated together. The
lack of statistically significant effects on
m2AChR binding did not result from higher
variability, because the significant deficits of
HC-3 binding were readily distinguishable
from the absence of effects on receptors (p <
0.03 for treatment × measure in the fore-
brain; p < 0.0004 for the three subregions).
Effects on DNA biomarkers. If the effects
of CPF on cholinergic systems are secondary to
general impairment of cell development, then
it would be expected that DNA biomarkers
would show adverse effects preceding, or
occurring simultaneously with, those for
cholinergic markers. However, during the
neonatal growth spurt, in which the forebrain
was experiencing a doubling of cell number
(Table 1), we did not find any significant
changes in DNA concentration (Figure 2A) or
content (Figure 2B) in the group exposed to 1
mg/kg/day of CPF. With the higher CPF
exposure (5 mg/kg/day), there was no signiﬁ-
cant change in the marker of cell packing den-
sity (DNA concentration), but because the
forebrain weight was reduced by about 10%
on PN4, the DNA content was similarly sub-
normal; this difference resolved by PN10. In
adolescence (PN30) and adulthood (PN60),
there was a significant overall reduction in
DNA concentration across the three subre-
gions. Although the differences in DNA con-
tent were not significant by themselves, this
negative result should be interpreted with cau-
tion, because the significant differences in
DNA concentration could not be distinguished
from the absence of signiﬁcant differences in
DNA content: none of the regions showed a
treatment × measure interaction when the two
DNA variables were compared in a repeated-
measures test. Indeed, comparing values for
the forebrain and cerebral cortex across all six
age points indicated a signiﬁcant treatment ×
age interaction for DNA content (p < 0.02).
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Figure 3. Effects of prenatal CPF exposure on postnatal development of cell protein biomarkers for (A) relative cell size (total protein/DNA) and membrane sur-
face area ([B] membrane protein concentration, [C] membrane/total protein). NS, not signiﬁcant. Data are presented as percentage change from control values
(Table 1), at the postnatal ages (days) indicated on the abscissa. Until weaning, measurements were made in the whole forebrain; for determinations in adoles-
cence and adulthood, the forebrain was divided into its constituent subregions. ANOVA results across ages and regions appear at the bottom of A–C. Tests of
individual points where the CPF group differs from the corresponding control were not carried out because either the global test or the lower-order tests after
separation of values by region failed to indicate an interaction of treatment × age. For variables showing an interaction of treatment × region, ANOVA results for
the regions appear below the appropriate bar clusters within the panels. Results for males and females were combined because of the absence of a treatment ×
sex effect after separation by region. 
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p < 0.05Nevertheless, the onset of decreased HC-3
binding in the forebrain of the low-dose group
was statistically distinguishable from the
absence of early changes in the DNA concen-
tration (treatment × measure, p < 0.03) or
content (p < 0.04).
Effects on protein biomarkers. Because the
adverse effects of CPF on cell development
might entail changes in cell growth or neuritic
differentiation, we also assessed the effects of
prenatal CPF exposure on protein biomarkers
of cell size and cell membrane area during the
period of rapid initial growth and during the
transition from adolescence to adulthood. The
ratio of total cell protein to DNA was subnor-
mal in the immediate neonatal period in ani-
mals exposed to CPF prenatally (Figure 3A).
However, by adolescence and adulthood, val-
ues became elevated in the cerebral cortex and
hippocampus. The membrane protein con-
centration showed a different pattern from
that of total protein: values tended to be sub-
normal in both the preweaning and postwean-
ing period (Figure 3B). To compare the
specific effects on membrane proteins, we
evaluated the ratio of membrane to total pro-
tein (Figure 3C): prenatal CPF exposure did
not have a statistically signiﬁcant effect in the
forebrain during the preweaning period, but
by PN30 and PN60, values became subnor-
mal in the cerebral cortex and hippocampus.
As above, combining the forebrain values with
those of the cerebral cortex did not change the
conclusions (total protein, p < 0.007 for treat-
ment × age; membrane protein, p < 0.009 for
the main treatment effect; membrane/total
protein, p < 0.05 for treatment, p < 0.1 for
treatment × age).
Discussion
Earlier work demonstrated the characteristics
of CPF-induced developmental neurotoxicity
consequent to postnatal exposure: brain cell
damage and loss, impaired synaptogenesis,
and deficits in synaptic function and related
behaviors (Barone et al. 2000; Pope 1999;
Slotkin 1999), all of which occur with thresh-
old doses below those required for growth
impairment. Deﬁcits in cholinergic function
appear almost immediately (Dam et al. 1999)
and persist into adolescence and adulthood
(Slotkin et al. 2001), accompanied by cogni-
tive defects related to impaired cholinergic
function (Levin et al. 2001). In contrast, pre-
natal CPF causes much less overall cell dam-
age and loss (Qiao et al. 2002), but there may
be speciﬁc, focal effects in forebrain areas pop-
ulated by cholinergic neurons (Lassiter et al.
2002; Qiao et al. 2002; White et al. 2002).
The present results indicate that, despite the
initial sparing, prenatal CPF exposure elicits
marked alterations that emerge in the postna-
tal period. Using treatment regimens that lie
below the threshold for fetal growth impair-
ment and that span the threshold for fetal
brain cholinesterase inhibition (Qiao et al.
2002), we identified postnatal deficits in
cholinergic activity that persisted into adult-
hood, associated with, but not necessarily
caused by, delayed, generalized effects on
brain cell development. Although CPF does
concentrate in milk (Mattsson et al. 2000), its
short biologic half-life (hours; Hunter et al.
1999; Lassiter et al. 1998) makes it extremely
unlikely that the observed effects of prenatal
exposure, terminated 2 days before birth,
reflect an indirect postnatal exposure from
residual CPF.
For ChAT activity, a constitutive marker
for cholinergic nerve terminals, low-dose
(1 mg/kg/day) prenatal CPF exposure
elicited slight initial postnatal elevations that
eventually regressed to normal or subnormal
values. The same effect was noted in the
fetal brain (Qiao et al. 2002), likely repre-
senting promotion of cell differentiation
consequent to cholinergic trophic effects
(Hohmann and Berger-Sweeney 1998;
Morley and Happe 2000; Navarro et al.
1989; Slotkin 1999). Presumably, at the
higher dose (5 mg/kg/day), these are offset by
deleterious actions, producing an “inverted-
U” dose–effect curve; the same phenomenon
has been noted for behavioral outcomes of
these treatments (Levin et al. 2002). Notably,
however, CPF did not elicit any long-term
deﬁcits in ChAT that indicate a speciﬁc loss
of cholinergic nerve terminals. In contrast,
however, HC-3 binding, which is responsive
to neuronal activity (Aubert et al. 1996;
Happe and Murrin 1992; Klemm and Kuhar
1979; Navarro et al. 1989; Simon et al. 1976;
Slotkin et al. 1990; Zahalka et al. 1992,
1993a), was markedly impaired. The reduc-
tion in presynaptic activity was not compen-
sated by up-regulation of cholinergic
receptors, as we found no significant alter-
ation of m2AChR binding. Accordingly, the
major change elicited by prenatal CPF
administration appears to be a reduction in
cholinergic synaptic function, effects that
were demonstrable even at exposure to 1
mg/kg/day, a dose that lies below the thresh-
old for maternal and fetal growth impairment
and for inhibition of fetal brain cholinesterase
(Qiao et al. 2002).
The time course for the effects of prenatal
CPF on HC-3 binding gave additional insight
into the underlying processes. Deficits were
apparent in the early neonatal period, before
the formation of the majority of forebrain
synapses; in this phase, ChAT was rising
rapidly in the controls, whereas the activity
marker, HC-3 binding, was relatively static.
Therefore, the fact that CPF lowered HC-3
binding while initially promoting ChAT activ-
ity indicates two separable actions on early
stages of cholinergic synaptic development.
HC-3 binding was nearly normal by weaning,
yet marked decrements reappeared in adoles-
cence and adulthood. Accordingly, prenatal
CPF elicits delayed-onset alterations, disrupt-
ing the “program” for the emergence of
cholinergic activity. The functional signifi-
cance of the later-occurring neurochemical
anomalies is corroborated by behavioral
deﬁcits in cholinergic contributions to work-
ing and reference memory that emerge in
adolescence and adulthood after fetal CPF
exposure (Levin et al. 2002). Notably, the
same exact pattern is elicited by prenatal
exposure to nicotine (Zahalka et al. 1992),
and therefore it is tempting to speculate that
these long-term alterations reﬂect disruption
consequent to elevated cholinergic activity
during a critical period in fetal development.
In addition to inhibiting cholinesterase, CPF,
like nicotine, interacts directly with nicotinic
cholinergic receptors (Katz et al. 1997), such
that exposures that do not cause significant
cholinesterase inhibition might still affect
cholinergic signaling. Regardless of the
underlying mechanism, the important fact is
that otherwise nontoxic prenatal exposures to
CPF elicit deﬁcits in cholinergic function that
influence cognitive performance in adoles-
cence and adulthood.
Our results for biomarkers of cell devel-
opment address the issue of whether the alter-
ations in cholinergic systems represent
selective actions of CPF or whether they are
secondary to general disruption of brain cell
proliferation and differentiation. Here, it is
useful to divide development into two pri-
mary stages as deﬁned by the normal ontoge-
netic patterns of cellular biomarkers. The rise
in DNA content, denoting cell acquisition,
was essentially complete by PN15, after
which further brain region growth involved
cell enlargement only (decreases in the DNA
concentration and increases in cell protein
markers). We did find an adverse effect of
prenatal CPF exposure on DNA content on
PN4, but the deﬁcit was limited to the high-
dose group and disappeared almost immedi-
ately, whereas effects on HC-3 binding
occurred with both dose regimens, were pre-
sent past PN4, and persisted in adolescence
and adulthood. During the transition from
adolescence to adulthood, there were statisti-
cally signiﬁcant reductions in DNA concen-
tration, an index of cell packing density, but
these were small in magnitude and were
inconsistent from region to region or between
the two doses. Nevertheless, because this
period is marked by synaptic remodeling and
apoptosis in late-developing regions such as
the hippocampus (Altman and Bayer 1990;
Bayer 1983; Bayer et al. 1982; Huttenlocher
1990; McWilliams and Lynch 1983; Scheetz
and Constantine-Paton 1994), it is conceiv-
able that the late-onset phase of the deﬁcits in
Articles | Qiao et al.
542 VOLUME 111 | NUMBER 4 | April 2003 • Environmental Health PerspectivesHC-3 binding is related to a more wide-
spread, delayed neurotoxic effect. On the
other hand, it is equally likely that the causal
relationship is in the opposite direction,
namely, that the emergence of cellular deﬁcits
reflects a primary impairment of cholinergic
activity. Improper synapse formation and
decreased synaptic function interfere with
transsynaptic signals that are critical to the
release of trophic factors that sustain neuronal
integrity (Frade and Barde 1998; Schwartz
1991). Cholinergic control of nerve growth
factor synthesis and release, for example, is
particularly prominent in the cerebral cortex
and hippocampus (Frade and Barde 1998),
and disruption of cholinergic communica-
tion, precisely in the early postnatal period in
which we found that CPF evoked a decrease
in the HC-3 marker, evokes widespread, sub-
sequent cellular and synaptic disruption
(Berger-Sweeney and Hohmann 1997;
Hohmann et al. 1988, 1991). Accordingly,
one likely scenario is that focal interference
with the differentiation of a small, targeted
population of fetal neurons (Lassiter et al.
2002; Qiao et al. 2002; White et al. 2002)
leads to deficits in cholinergic activity that
emerge postnatally, with a consequent imped-
iment to neurotrophic factors that sustain
neuronal integrity, culminating in late-onset
neural damage and behavioral deﬁcits (Levin
et al. 2002).
Similar interpretations can be applied to
the effects of prenatal CPF exposure on pro-
tein biomarkers of cell growth (total protein/
DNA) and neuritic extension (membrane pro-
tein concentration, membrane/total protein).
Changes for these factors were more wide-
spread and robust than those for DNA con-
tent or concentration, although again, the
magnitude and timing of the effects appeared
to be incompatible with their playing a
causative role in the deterioration of choliner-
gic function. In particular, we found late-
onset cell enlargement in the cerebral cortex
and hippocampus (increased total protein/
DNA). Because this biochemical change could
represent either a larger perikaryon or more
neuritic extensions, we also assessed mem-
brane protein markers in both absolute (mem-
brane protein concentration) and relative
(membrane/total protein) terms; an increase
in extensions would augment membrane pro-
tein proportionally more than total protein.
However, these markers indicated a decrease in
absolute and relative membrane protein, con-
sistent with a loss of membrane surface area,
implicitly representative of reductions in neu-
ritic projections. Although that interpretation
needs to be confirmed with morphologic
examinations, this type of defect could clearly
contribute to a generalized decrease in neural
activity, intensifying the loss of cholinergic
function. In vitro models of neural develop-
ment have demonstrated direct impairment of
axonogenesis by CPF (Das and Barone 1999),
but the late emergence of the deﬁcits in pro-
tein biomarkers argues against this as an
underlying mechanism and is more compati-
ble with delayed-onset interference with neu-
rotrophic regulation.
The biochemical approach used in the
present study has two distinct limitations in
interpreting the results related to measure-
ments of DNA and cell proteins. First,
homogenization of brain regions containing
diverse neuronal groupings means that even
drastic effects on a speciﬁc set of neurons may
go unnoticed because of dilution with unaf-
fected areas. Accordingly, the fact that we
found signiﬁcant alterations in biomarkers of
cell number, cell packing density, and cell
protein complement indicates that much
larger changes may be identified when neu-
roanatomical approaches are taken. Second,
unlike the situation with biomarkers that are
specific to cholinergic innervation, measure-
ments of DNA and protein are common to
neurons and glia. Given the fact that forebrain
neurogenesis is nearly completed by birth, our
ﬁnding of late-onset changes in the postnatal
period suggests that many of these changes
involve either postmitotic damage or effects
on glial cells. We recently reported that the
CPF regimen used here also produces late-
onset deﬁcits in the expression of myelin basic
protein, a marker that is speciﬁc for oligoden-
drocytes (Garcia et al. 2003), suggesting that
at least some of the changes may involve glial
cells. However, these changes do not rule out
the possibility of late-onset neuronal apoptosis
or indirect neuronal damage secondary to
adverse effects on glia. Indeed, two prelimi-
nary reports suggest that prenatal CPF expo-
sure can disrupt architectural organization of
speciﬁc forebrain subregions, including apop-
tosis and changes in cell migration (Lassiter et
al. 2002; White et al. 2002). As discussed
above, such alterations are likely to trigger
later neuronal loss (Berger-Sweeney and
Hohmann 1997; Hohmann and Berger-
Sweeney 1998; Hohmann et al. 1988, 1991).
Again, neuroanatomical studies demonstrating
targeted effects on different types of cells and
on different brain nuclei, and specifically
assessing apoptosis, are needed to resolve
this issue.
In conclusion, prenatal CPF exposure
compromises the subsequent development of
cholinergic synaptic function, characterized by
deficits in an index of neural activity
(decreased HC-3 binding) without substantial
loss of nerve terminals (little or no change in
ChAT). These changes persist into adolescence
and adulthood and correspond to the long-
term defects in cholinergic components of
working and reference memory (Levin et al.
2002). CPF also causes delayed abnormalities
of cellular characteristics in forebrain areas
involved in cognitive function, with changes
indicative of reduced cell density, increased
cell size, and loss of neuritic extensions. The
alterations in cholinergic function do not
appear to depend directly upon the timing
and magnitude of the general cellular deﬁcits;
rather, the cellular effects may actually result
from defective synaptic transmission. CPF has
adverse effects on cholinergic synaptic func-
tion and behavior that are elicited even at
exposures below the threshold for overt fetal
or maternal toxicity, with a window of vulner-
ability extending from prenatal through
neonatal stages (Dam et al. 1999; Levin et al.
2001, 2002; Slotkin et al. 2001). Accordingly,
developmental neurotoxicity consequent to
fetal or childhood CPF exposure may occur in
settings in which immediate symptoms of
intoxication are absent.
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